Diagnostic assay that classifies non-Hodgkin’s lymphoma specifically diffuse large B cell lymphoma (DLBCL) into two groups, which respond differently to chemotherapy.
- Uses gene expression profiling for classification.
- Provides classification of sub-group for a better selection of more specific and effective treatments.
An estimated 66 thousand people living in the US will be diagnosed with non-Hodgkin’s lymphoma in a year. Among NHL, diffuse large B cell lymphoma is the most common subtype. There are two sub-groups of and each responds differently to chemotherapy. In fact, 40-50% of the patients treated for non-Hodgkin’s lymphoma are not cured by conventional chemotherapy because different types of lymphoma respond differently to treatment. By pre-screening patients with these methodologies Doctors can predict treatment response and identify therapies that target specific disease mechanism in lymphomas. Particular, this technology will facilitate the development of specific NF-ÎºB pathway inhibitors targeted to specific patients with lymphomas.
Activation of the NF-ÎºB pathways has been associated with lymphomagenesis and tumor resistance to chemotherapy. However, the contribution of the canonical and noncanonical NF-ÎºB pathways to lymphoma biology and clinical outcome remains unknown. Therefore, if the status of activation of each NF-ÎºB pathway could be identified prior to treatment, patients would benefit from the use of specific inhibitors that target the NF-ÎºB pathway altered in order to overcome chemotherapy resistance that is inherent in some types of lymphoma but not in others. Dr. Bernal-Mizrachi has identified different gene expression profiles that predict the status of activation of the canonical and noncanonical NF-ÎºB pathway in DLBCL to be used to screen patients with non-Hodgkin’s lymphoma. It was discovered that the activation of the noncanonical NF-ÎºB pathway associated with a better response to standard treatments (RCHOP) in of non-Hodgkin lymphomas. Chemotherapy with targeted inactivation of the altered NF-ÎºB activity would be more effective for patients DLBCL. Therefore, by identifying the gene signature of the cancer cells, better treatments can be selected.
Research has been conducted in vitro with non-Hodgkin’s lymphoma cell lines.